Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

OncoCyte Corp ($OCX) stock surged as the company announced positive results in the development of a blood-based diagnostic test for lung cancer. the optimized final predictive algorithm showed sensitivity of 95%, specificity of 73% and area under the curve of 0.92. The test is expected to help reduce the number of lung biopsies related to the diagnosis of lung cancer. The company plans to complete the validation studies and obtain CLIA certification, after which it plans to launch the test.
The stock reacted positively to the news and jumped over 23 percent in the previous session, taking its Year to Date to 4 percent. The stock gained 81 percent in the past 12 months.

Flexion Therapeutics Inc. ($FLXN) announced that results from a health economics analysis carried out on Zilretta (FX006) for the treatment of knee osteoarthritis pain. The study aimed to estimate Zilretta's impact on patients' quality of life and it cost effectiveness with other therapies. The company has already filed its marketing application with the USFDA and is expected to receive the decision by October 6. The study demonstrated that Zilretta has the potential to be a cost-effective therapy for treating knee osteoarthritis (OA) pain.
The company stock reacted positively to the news and jumped over 8 percent in its previous trading session. The stock price gained 82 percent in the past 12 months.

 

AstraZeneca ($AZN) reported positive results from a Phase 3 clinical trial, ZONDA, assessing IL-5 inhibitor benralizumab in patients with sever asthma. The study achieved its primary endpoint of showing a statistically significant reduction in daily maintenance oral corticosteroid use for two benralizumab dosing regimens versus placebo. The mean reduction shown by the results was 75% in the test group compared to 25% for placebo.

Community Health Systems ($CYH) announced that it has terminated the discussions regarding the sale of its Indiana hospitals. The company was reportedly offered $2.4 billion for the hospitals.

Regeneron Pharmaceuticals ($REGN) and Sanofi ($SNY) announced receiving the FDA approval for their  Kevzara (sarilumab) biotech drug for treating adults with moderate to severely active rheumatoid arthritis. The duo earlier won the FDA approval for their Dupixent treatment for severe atopic dermatitis in March. Kevzara is expected to come with list price of $39K/year for the 200 mg and 150 mg doses.

Merck ($MRK) announced positive results from a Phase 2 clinical trial assessing MK-7264 for treating chronic cough. The study met its primary endpoint of a statistically significant reduction in awake cough frequency from baseline compared to placebo (37%; p=0.003).  Merck obtained the rights to MK-7264, an orally administered non-narcotic P2X3 receptor antagonist, via its acquisition of Afferent a year ago.

 

Elite Pharmaceuticals ($ELTP) announced acquiring the ANDA for antidepressant trimipramine maleate from Mikah Pharma, LLC. It will help the company in ensuring smooth supply of the product in the US. The marketing of the product will be undertaken by Dr. Reddy’s Labs.

NeuroMetrix ($NURO) announced receiving patent approval from the USPTO. The company has been granted Patent No. 9,656,070 protecting its Quell device. The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation.

 

Perrigo ($PRGO) announced its fourth quarter revenue at $1.33 billion, beating consensus estimate. Its net loss for the quarter stood at $1.36 billion. For the full year, the company’s loss stood at $4.01 billion while its revenue was reported at $5.28 billion.

Taro Pharmaceuticals ($TARO) reported its revenue for the fourth quarter at $196.4 million while its earnings for the same period stood at $83 million. For the entire year, the company earned profit of $456.4 million, or $11.05 per share. Its revenue for the period stood at $879.4 million.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
HC Wainwright
Reiterates
Presbia PLC (LENS)
Buy
$12.00
N/A

Gainers (% price change) Last Trade Change Mkt Cap
Oclaro, Inc. OCLR 9.37 +0.87 (10.24%) 1.60B
Amicus Therapeutics, Inc. FOLD 8.41 +0.64 (8.24%) 1.21B
Cumberland CPIX 7.00 +0.47 (7.20%) 106.22M
BioTime, Inc. BTX 3.30 +0.22 (7.14%) 369.49M
Misonix, Inc. MSON 10.80 +0.65 (6.40%) 102.50M
Losers (% price change)
Sarepta Therapeutics Inc SRPT 32.68 -1.96 (-5.66%) 1.74B
Antares Pharma Inc ATRS 2.45 -0.13 (-5.04%) 383.51M
Momenta Pharmaceuticals MNTA 14.80 -0.75 (-4.82%) 1.07B
Sangamo Therapeutics Inc SGMO 7.45 -0.35 (-4.49%) 525.83M
BioCryst Pharmaceuticals BCRX 5.24 -0.24 (-4.38%) 393.41M
Most Actives (dollar volume)
Amgen, Inc. AMGN 153.02 -3.49 (-2.23%) 111.50B
Pfizer Inc. PFE 32.12 -0.34 (-1.05%) 192.70B
Celgene Corporation CELG 115.71 -1.22 (-1.04%) 89.99B
UnitedHealth Group Inc UNH 174.70 +2.11 (1.22%) 169.47B
Johnson & Johnson JNJ 127.26 +0.28 (0.22%) 342.90B